177 related articles for article (PubMed ID: 6185525)
1. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
Kawamura S; Kishino B; Tajima K; Mashita K; Tarui S
J Clin Endocrinol Metab; 1983 Mar; 56(3):507-12. PubMed ID: 6185525
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse.
Gong ST; Chao IM
J Formos Med Assoc; 1991 Dec; 90(12):1155-62. PubMed ID: 1724781
[TBL] [Abstract][Full Text] [Related]
3. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
4. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
5. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
6. Correlation of sequential changes in serum thyroglobulin, triiodothyronine, and thyroxine in patients with Graves' disease and subacute thyroiditis.
Izumi M; Larsen PR
Metabolism; 1978 Apr; 27(4):449-60. PubMed ID: 580305
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
9. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
Takamatsu J; Kuma K; Mozai T
J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
[TBL] [Abstract][Full Text] [Related]
10. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
[TBL] [Abstract][Full Text] [Related]
11. Effect of therapy on the serum thyroglobulin concentration in patients with toxic diffuse goiter, toxic nodular goiter and toxic adenoma.
Ericsson UB; Tegler L; Dymling JF; Thorell JI
J Endocrinol Invest; 1987 Aug; 10(4):351-7. PubMed ID: 2445808
[TBL] [Abstract][Full Text] [Related]
12. Long term treatment of Graves' hyperthyroidism with sodium ipodate.
Shen DC; Wu SY; Chopra IJ; Huang HW; Shian LR; Bian TY; Jeng CY; Solomon DH
J Clin Endocrinol Metab; 1985 Oct; 61(4):723-7. PubMed ID: 3928675
[TBL] [Abstract][Full Text] [Related]
13. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
[TBL] [Abstract][Full Text] [Related]
14. Decrease of immunoglobulin G-Fc receptor-bearing T lymphocytes in Graves' disease.
Mori H; Amino N; Iwatani Y; Asari S; Izumiguchi Y; Kumahara Y; Miyai K
J Clin Endocrinol Metab; 1982 Sep; 55(3):399-402. PubMed ID: 6178751
[TBL] [Abstract][Full Text] [Related]
15. Short and long term effects of radioiodine and antithyroid drugs on T4 binding proteins, free T4 and T3, during Graves' disease therapy.
Jaffiol C; Baldet L; Robin M; Papachristou C; Lapinski H; Mirouze J
Horm Metab Res; 1977 Jan; 9(1):73-81. PubMed ID: 66177
[TBL] [Abstract][Full Text] [Related]
16. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
Khanna CM; Shankar LR; Jaggi CB; Bansal JK; Chugh P
J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
[TBL] [Abstract][Full Text] [Related]
17. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
18. [The prognostic application of thyroid volume determination in patients with Graves' disease].
Sakane S
Nihon Naibunpi Gakkai Zasshi; 1990 May; 66(5):543-56. PubMed ID: 1696557
[TBL] [Abstract][Full Text] [Related]
19. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to lithium in treated Graves' disease: effects on serum T4, T3 and reverse T3.
Burman KD; Dimond RC; Earll JM; Wright FD; Wartofsky L
J Clin Endocrinol Metab; 1976 Sep; 43(3):606-13. PubMed ID: 989049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
